Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124881) titled 'Trastuzumab Rezetecan Antibody-Drug Conjugate Combined with Retlirafusp a in Patients with HER2-Positive and Potentially Immunotherapy-Sensitive Gastric or Gastroesophageal Junction Adenocarcinoma, A Prospective Phase Ib Trial' on May 19.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Condition:
Potentially Immunotherapy-Sensitive Gastric or Gastroesophageal Junction Adenocarcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-31
Target Sample Size: Im...